Anviro Therapeutics

Anviro Therapeutics

Anviro Therapeutics is a biotechnology company developing broad spectrum antiviral therapies.

All edits

Edits today
Lax Mariappan
Lax Mariappan edited 21 hours ago
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2015
Edits on 3 August, 2020
Marie Gabrielle Laguna-Bedia
Marie Gabrielle Laguna-Bedia edited on 3 August, 2020 6:41 am
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 1 August, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 1 August, 2020 6:08 pm
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
650,000
Golden AI
Golden AI edited on 1 August, 2020 6:08 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 25 July, 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 25 July, 2019 1:44 am
Edits made to:
Article (+13/-13 characters)
Article

Anviro Therapeutics is a privately held, biotechnology company making broad-spectrum antiviral therapeutics that is based in Orem, Utah and was founded in 2015 by Kyle Lane and Matthew CryerMatthew Cryer. The company is developing treatments for several infectious diseases, including pox viruses and herpes viruses. Their lead program is based on technology discovered by researchers at Brigham Young University (BYU).

Golden AI
Golden AI edited on 24 July, 2019 12:03 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 30 May, 2019
Jan Stepnicka
Jan Stepnicka approved a suggestion from Golden's AI on 30 May, 2019 1:35 pm
Edits made to:
Article (+9/-9 characters)
Article

Anviro Therapeutics is a privately held, biotechnology company making broad-spectrum antiviral therapeutics that is based in Orem, Utah and was founded in 2015 by Kyle LaneKyle Lane and Matthew Cryer. The company is developing treatments for several infectious diseases, including pox viruses and herpes viruses. Their lead program is based on technology discovered by researchers at Brigham Young University (BYU).

Edits on 30 May, 2019
Golden AI
Golden AI edited on 30 May, 2019 4:53 am
Edits made to:
Infobox (+1 properties)
Infobox
Founder
Edits on 28 March, 2019
Dawson Sewell
Dawson Sewell edited on 28 March, 2019 9:57 pm
Edits made to:
Infobox (+3/-1 properties)
Timeline (+2 events) (+242 characters)
Description (+94/-26 characters)
Article (+249/-12 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)
Topic thumbnail

Anviro Therapeutics

Antiherpes therapy company

Anviro Therapeutics is a biotechnology company developing broad spectrum antiviral therapies.

Article

Anviro Therapeutics is a privately held, biotechnology company making broad-spectrum antiviral companytherapeutics that is based in Orem, Utah and was founded in 2015 by Kyle Lane and Matthew Cryer. The company is developing treatments for several infectious diseases, including pox viruses and herpes viruses. Their lead program is based on technology discovered by researchers at Brigham Young University (BYU).

...

In virtovitro and in vivo assays have shown potential for KPB-100 as a topical treatment for several DNA-viruses, including:

...

Funding

Seed

On January 1, 2016 Anviro Therapeutics completed their seed funding round with $650,000 in funding from undisclosed investors.

Infobox
Categories
Related Topics
Timeline

2016

Seed funding

On January 1, 2016 Anviro Therapeutics completed their seed funding round with $650,000 in funding from undisclosed investors.

March 28, 2015

Founding of Anviro Therapeutics

Anviro Therapeutics was founded in 2015 by Kyle Lane and Matthew Cryer.

Edits on 4 February, 2019
Golden AI"Import data"
Golden AI edited on 4 February, 2019 10:54 pm
Edits made to:
Infobox (+1 properties)
People (+1 rows) (+2 cells) (+15 characters)
People

Name
Role
Related Golden topics

Tom Fast

Advisor

Infobox
Edits on 21 January, 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 January, 2019 10:17 pm
Edits made to:
Infobox (+3/-3 properties)
Infobox
Edits on 15 January, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 January, 2019 2:12 pm
Edits made to:
Article (+24/-24 characters)
Article

Anviro Therapeutics is a privately held, broad-spectrum antiviral company based in Orem, Utah. The company is developing treatments for several infectious diseases, including pox viruses and herpes viruses. Their lead program is based on technology discovered by researchers at Brigham Young UniversityBrigham Young University (BYU).

Edits on 10 January, 2019
Golden AI
Golden AI edited on 10 January, 2019 10:19 am
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 9 January, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 January, 2019 8:49 pm
Edits made to:
Article (+10/-10 characters)
Article

Anviro Therapeutics is a privately held, broad-spectrum antiviral company based in Orem, UtahOrem, Utah. The company is developing treatments for several infectious diseases, including pox viruses and herpes viruses. Their lead program is based on technology discovered by researchers at Brigham Young University (BYU).

Edits on 6 January, 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 6 January, 2019 8:07 pm
Edits made to:
Infobox (+2/-2 properties)
Article (+1200 characters)
People (+1 rows) (+2 cells) (+53/-16 characters)
Article

Anviro Therapeutics is a privately held, broad-spectrum antiviral company based in Orem, Utah. The company is developing treatments for several infectious diseases, including pox viruses and herpes viruses. Their lead program is based on technology discovered by researchers at Brigham Young University (BYU).

The compound, designated KPB-100, has antiviral properties across a range of viruses in the herpes and pox virus families. KPB-100 is a small molecule that utilizes a mechanism of action directed at morphogenesis inhibition, which allows it to be used as a treatment against strains of the herpes virus that are resistant to frontline treatments.

In virto and in vivo assays have shown potential for KPB-100 as a topical treatment for several DNA-viruses, including:

  • Wildtype and mutant HSV-1 and HSV-2
  • Herpes zoster (shingles)
  • Progressive vaccinia
  • Adverse effects of smallpox vaccination

Anviro's expected timeline for the product is as follows:

  • 2018 - Submission of Investigational New Drug (IND) Application to the USFDA
  • 2018 - 2019 - Small Scale Clinical Trial (Phase 1)
  • 2020 - 2023 - Large Scale Clinical Trial (Phase 2)
  • 2023 - 2025 - Comparative Clinical Trial (Phase 3)
  • 2026 - Commercial Launch
People

Name
Role
Related Golden topics

Kyle Lane

EmployeeCOO

Marc Hansen

EmployeeActing Chief Scientific Officer

Mark Elder

CFO

Matthew Cryer

Founder & CEO

Infobox
Edits on 12 December, 2018
Golden AI"Import data"
Golden AI edited on 12 December, 2018 1:05 am
Edits made to:
Infobox (+1 properties)
People (+4 rows) (+8 cells) (+77 characters)
Categories (+1 topics)
People

Name
Role
Related Golden topics

Alonzo Cook

Employee

Kyle Lane

Employee

Marc Hansen

Employee

Merritt Andrus

Employee

Infobox
Categories
Edits on 14 November, 2018
Melanie Manipula"Approved suggestion from source: http://anvirotherapeutics.com"
Melanie Manipula approved a suggestion from Golden's AI on 14 November, 2018 9:30 pm
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 14 November, 2018
Jude Gomila"Approved suggestion from source: http://anvirotherapeutics.com"
Jude Gomila approved a suggestion from Golden's AI on 14 November, 2018 3:12 am
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 19 July, 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 July, 2018 8:46 pm
Infobox
Location
Golden AI"Update locations in infobox"
Golden AI edited on 19 July, 2018 8:42 pm
Infobox
Location
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.